Home / Health / New drugs may slash TAVR heart risks
New drugs may slash TAVR heart risks
2 Apr
Summary
- SGLT2 inhibitors reduced mortality, heart failure, and rehospitalization.
- Colchicine lowered risks of pacemaker implantation and valve dysfunction.
- Studies presented at ACC 2026 on post-TAVR pharmacotherapies.
At the American College of Cardiology (ACC) 2026 conference, retrospective analyses indicated that certain pharmacotherapies may improve outcomes for patients who have undergone a transcatheter aortic valve replacement (TAVR) procedure. These studies utilized data from the TriNetX Global Collaborative Network.
One analysis of over 55,000 patients found that SGLT2 inhibitor treatment post-TAVR was associated with reduced all-cause mortality, heart failure, and rehospitalization. Over five years, this group also saw fewer strokes and heart attacks.
Another study involving over 8,500 matched patients indicated that colchicine treatment after TAVR lowered the risk of pacemaker implantation and prosthetic valve dysfunction. However, this treatment did not significantly affect the risk of stroke or heart failure and was associated with an increased risk of acute kidney injury.
While these findings are preliminary and await confirmation through randomized controlled trials, they offer a strategic direction for future research and potential label expansion for these drug classes.
